When asked how to find investment targets, Lu Kongming said that 50% depends on personality traits , such as integrity, professionalism, and diligence; the other 50% depends on patents and whether the technology can compete with international competition.
Diamond Biotechnology provides innovative assistance from the laboratory to the market, combining new drug research and development and consulting teams. In addition, it will provide "friendly exit". When a company has reached maturity and will no longer grow, it will exit the market, and stocks will not be sold easily.
Judging from operating performance, revenue in 2021 is 3.063 billion yuan, pre-tax earnings are 2.96 billion yuan, and earnings per share are 4.5 yuan. It has delivered a profit report card of nearly half of its capital indonesia telegram for two consecutive years. Looking forward to the future, investment targets will target the two major fields of cell therapy and nucleic acid drugs, with the goal of incubating biotech unicorns.
Whether it is surgery simulation or pain relief, it all requires the assistance of VR equipment. Both people, who work in different organizations, said that it doesn't matter which device they use, as long as the software supports what they need. Spiegel also believes that many people who buy such headsets only view these devices as entertainment devices and have no idea of the health applications.
Diamond Biotechnology was initiated and established by Zhongtian Biotechnology Group. When the company was established, it combined the support of Fubon Financial Holdings, Taishin Financial Holdings and Runtai Group. Lu Kongming specially named four business leaders to thank them for their support from the early days until now. Including Fubon Media Chairman Cai Mingzhong, Fubon Financial Holdings Chairman Cai Mingxing, Taishin Financial Holdings Chairman Wu Dongliang, and Runtai Group founder Yin Yanliang.
- Board index
- All times are UTC
- Delete cookies
- Contact us